Merck KGaA has announced that their new formulation of Rebif has been recommended for marketing authorization in the treatment of relapsing multiple sclerosis.

According to an article on Pharmabiz.com this formulation is designed to make the treatment with Rebif better by making the injections more tolerable and reducing immunogenicity.

I would recommend that you read the full article as posted at the Pharmabiz site.

- Vince